MedTrace Logo

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

NCT06492317 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-07-09

No results posted yet for this study

Summary

A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma

Conditions

  • HER2-positive Gastric Cancer

Interventions

DRUG

Disitamab Vedotin

Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)

DRUG

Cadonilimab

Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-06
Primary Completion
2026-07-06
Completion
2027-07-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492317 on ClinicalTrials.gov